Bondwell Technologies LP

College Station, TX · Founded 2020 · Biotech · Private

Functionalized biomaterial membrane for viral vector purification and separation

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: College Station, TX
Founded: 2020
Latest Form D: $451K, Nov 2023
Total capital: $5.9M

Federal grants: $5.4M; 6 awards · 2021–2025; Rank in peer group#6 of 20
Private capital raised: $451K; 1 Form D · last Nov 2023; 35 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 2; 3 pending · first 2023; Rank in peer group#8 of 20

Capital timeline

Latest events

Feb 2025Federal grantHealth and Human S · Phase II · A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing$1.2M
Feb 2024Federal grantHealth and Human S · Phase II · A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing$1.3M
Nov 2023Private capital raisedForm D · SEC · 1st filing$451K
Apr 2023Federal grantHealth and Human S · Phase I · Novel, Targeted Method for Bacteriophage Purification$275K
Aug 2022Federal grantHealth and Human S · Phase II · A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing$821K
May 2022Federal grantHealth and Human S · Phase I · Novel biomaterial for enantiomer separation$276K
Sep 2021Federal grantHealth and Human S · Phase II · A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing$1.6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

26months

from Bondwell Technologies LP’s first federal award to its first private round.

First federal award · Sep 2021: Health and Human S · $1.6M
First Form D · Nov 2023: $451K · 1st Form D
Awards before first raise: 4 awards

An association in public records, not a cause or a prediction.

Standing among 20 peers

Line = median

Biotech · Material

Federal grants#6 · top 30%
Granted patents#8 · top 40%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Sarah BondosResearcherExecutive OfficerLinked by 2 patents
David HowellResearcherExecutive OfficerLinked by $4.9M in grants as PI
Clinton JonesExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 5

Dec 18, 2025PendingFunctionalized Ubx Protein Materials For Enhanced Purification Of AntibodiesUSPTOApplication 19228899
Apr 15, 2025GrantedSelf-assembly Of Protein-based Biomaterials With Multiple MorphologiesUSPTOUS 12,275,765
Apr 11, 2024PendingProtein-based Material For BiocatalysisUSPTOApplication 18263833

Show all 5 patent records

Functionalized Ubx Protein Materials For Enhanced Purification Of AntibodiesDec 18, 2025 · Application 19228899Pending
Self-assembly Of Protein-based Biomaterials With Multiple MorphologiesApr 15, 2025 · US 12,275,765Granted
Protein-based Material For BiocatalysisApr 11, 2024 · Application 18263833Pending
Self-assembly Of Protein-based Biomaterials With Multiple MorphologiesMar 14, 2023 · US 11,603,393Granted
Protein-based Material For BiocatalysisApplication PCTUS2022014944Pending

BIOTECERA INC.Similar federal contract value in Biotech · null in contracts
DRIVE THERAPEUTICS, L.L.C.Similar federal contract value in Biotech · null in contracts
Knudra DiagnosticsSimilar federal contract value in Biotech · null in contracts
PALENA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Trove Labs IncSimilar federal contract value in Biotech · null in contracts
PHAGE REFINERY, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.